Table 1.
Clinical and pathological characteristics in 412 eligible lung cancer patients
| Variables | Categories | Total patients (n = 412) No. of patients (%) | |||
|---|---|---|---|---|---|
| LC patients | NSCLC (n = 336) | SCLC (n = 58) | |||
| Stage I–III (n = 247) | Stage IV (n = 89) | ||||
| Gender* | Male | 317 (76.90) | 196 (79.40) | 59 (66.30) | 49 (84.50) |
| Female | 95 (23.10) | 51 (20.60) | 30 (33.70) | 9 (15.50) | |
| Age | Year | 60.33 ± 8.97 | 60.42 ± 8.60 | 60.62 ± 9.74 | 58.98 ± 8.47 |
| Tobacco** | Yes | 247 (60.00) | 157 (63.60) | 41 (46.10) | 40 (69.00) |
| No | 165 (40.00) | 90 (36.40) | 48 (53.90) | 18 (31.00) | |
| Alcohol | Yes | 96 (23.30) | 63 (25.50) | 19 (21.30) | 13 (22.40) |
| No | 316 (76.70) | 184 (74.50) | 70 (78.70) | 45 (77.60) | |
| Hypertension* | Yes | 68 (16.50) | 35 (14.20) | 11 (12.40) | 17 (29.30) |
| No | 344 (83.50) | 212 (85.8) | 78 (87.60) | 41 (70.70) | |
| Diabetes | Yes | 18 (4.40) | 11 (4.50) | 3 (3.40) | 3 (5.20) |
| No | 394 (95.60) | 236 (95.50) | 86 (96.6) | 55 (94.80) | |
| ECOG* | 0 | 303 (73.50) | 192 (77.70) | 57 (64.00) | 39 (67.20) |
| ≥1 | 109 (26.50) | 55 (22.30) | 32 (36.00) | 19 (32.80) | |
| Tumor size** | T1–T2 | 182 (44.20) | 164 (66.40) | 9 (10.10) | 7 (12.10) |
| T3–T4 | 82 (19.90) | 64 (25.90) | 12 (13.50) | 4 (6.90) | |
| Lymph node*** | N0 | 122 (29.60) | 116 (47.00) | 4 (4.50) | 1 (1.70) |
| N1–N3 | 148 (35.90) | 115 (46.60) | 19 (21.30) | 10 (17.20) | |
| Differentiation*** | Poor | 75 (18.20) | 51 (20.60) | 19 (21.30) | 5 (8.60) |
| Well | 111 (26.90) | 103 (41.70) | 8 (9.00) | 0 (0) | |
| Therapy | S | 59 (14.30) | 59 (23.89) | 0 (0) | 0 (0) |
| SC | 172 (56.10) | 152 (61.45) | 0 (0) | 12 (20.69) | |
| C | 181 (43.90) | 36 (8.74) | 89 (100) | 46 (79.31) | |
| Metastasis | Brain | 11 (2.70) | N/A | 10 (11.24) | 1 (1.72) |
| Bone | 42 (10.20) | N/A | 30 (33.70) | 6 (1.03) | |
| Contralateral lung | 12 (2.90) | N/A | 8 (8.99) | 4 (6.90) | |
| Lymphatic | 13 (3.20) | N/A | 7 (7.87) | 6 (10.34) | |
| Malign pleural effusion | 26 (6.30) | N/A | 19 (21.35) | 4 (6.90) | |
| Other | 28 (6.80) | N/A | 15 (16.85) | 11 (18.97) | |
| Leukocyte | *109/L | 6.61 (2.66–19.04) | 6.54 (2.78–17.59) | 7.10 (2.66–19.04) | 6.80 ± 2.28 |
| Neutrophil | *109/L | 4.37 (1.34–15.45) | 4.24 (1.34–13.36) | 4.82 (1.38–15.45) | 4.15 (1.54–11.36) |
| Lymphocyte* | *109/L | 1.60 (0.19–15.43) | 1.64 (0.19–15.43) | 1.51 (0.43–3.50) | 1.59 (0.50–3.70) |
| Monocyte | *109/L | 0.43 (0.01–1.52) | 0.42 (0.01–1.52) | 0.55 ± 0.28 | 0.50 ± 0.24 |
| Platelet | *109/L | 210.00 (59.00–555.00) | 218.63 ± 74.81 | 228.85 ± 91.17 | 215.00 (62.00–555.00) |
| Fib | mg/dL | 3.81 ± 1.27 | 3.68 ± 1.28 | 3.92 (1.32–6.41) | 4.04 ± 1.09 |
| Alb* | g/L | 39.17 (10.3–50.00) | 39.38 (10.30–50.00) | 37.93 ± 4.02 | 39.37 (29.45–46.83) |
| NLR** | 2.74 (0.10–13.36) | 2.61 (0.10–13.36) | 3.28 (0.91–13.36) | 2.77 (1.00–12.63) | |
| PLR | 136.58 (10.56–1173.68) | 131.43 (10.56–1173.68) | 152.20 (34.57–593.55) | 137.15 (51.29–383.33) | |
| MLR** | 0.28 (0.003–1.33) | 0.26 (0.003–1.14) | 0.39 (0.02–1.07) | 0.29 (0.08–1.33) | |
| AFR | 10.04 (4.54–34.39) | 10.94 (4.54–34.39) | 9.30 (5.19–27.80) | 9.38 (6.01–30.63) | |
Abbreviation: N/A, not available; ECOG score, eastern cooperative oncology group score; Fib, fibrinogen; Alb, albumin; NLR, neutrophil‐lymphocyte ratio; PLR, platelet‐lymphocyte ratio; MLR, monocyte‐lymphocyte ratio; AFR, albumin/fibrinogen ratio. S, surgical resection without adjuvant chemo‐radiotherapy; SC, surgical resection with adjuvant chemo‐radiotherapy; C, chemo‐radiotherapy without surgery; *P < 0.05, **P < 0.01, ***P < 0.001.